Authors

Rachel Frederick

MBBS, Advanced Trainee General Medicine, University Hospital Geelong, Geelong, Vic

Sodium–glucose cotransporter 2 inhibitors for chronic kidney disease: Why, when and when not

This article aims to provide evidence-based information to GPs, aiding the decision to initiate sodium–glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease patients.